Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

36.0%

9 terminated/withdrawn out of 25 trials

Success Rate

52.6%

-33.9% vs industry average

Late-Stage Pipeline

36%

9 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

2 recruiting4 with results4 withdrawn

Enrollment Performance

Analytics

Phase 2

11(45.8%)

Phase 4

6(25.0%)

Phase 1

4(16.7%)

Phase 3

3(12.5%)

24Total

Phase 2(11)

Phase 4(6)

Phase 1(4)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT04904562Phase 4Terminated

Angiotensin II for Distributive Shock

Role: collaborator

NCT04901169Phase 2Active Not Recruiting

Angiotensin II in Liver Transplantation

Role: collaborator

NCT05824767Phase 4Completed

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

Role: collaborator

NCT06487585Phase 4Recruiting

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Role: collaborator

NCT06122987Phase 4Recruiting

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Role: collaborator

NCT05193370Phase 4Withdrawn

Angiotensin II vs. Vasopressin in Septic Shock

Role: collaborator

NCT04529005Phase 4Completed

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

Role: collaborator

NCT03395704Phase 2Completed

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Role: lead

NCT03381833Phase 2Terminated

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Role: lead

NCT03623529Phase 2Unknown

A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

Role: lead

NCT03431077Phase 2Completed

A Study of LJPC-501 in Pediatric Patients With Hypotension

Role: lead

NCT02338843Phase 3Completed

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

Role: lead

NCT03245528Unknown

Expanded Access for LJPC-501

Role: lead

NCT02155673Phase 2Completed

A Phase 2 Extension Study of Study GCS-100-CS-4002

Role: lead

NCT01906307Phase 1Terminated

A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

Role: lead

NCT01843790Phase 2Completed

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Role: lead

NCT00390091Phase 2Withdrawn

Study of LJP 394 (Abetimus Sodium) in Lupus Patients

Role: lead

NCT02312050Phase 2Unknown

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Role: lead

NCT02333955Phase 2Withdrawn

A Phase 2 Extension of Study GCS-100-CS-4003

Role: lead

NCT00776802Phase 1Withdrawn

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Role: lead